Sovrin Shah, MD
Urology · New York, NYNPI 1245211663
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,359 of the $13,943 with a category attached, or 81.5%. It is spread thinly across 41 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.
Across 236 payments — averaging $59.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Procept Biorobotics Corporation$2K
- Medtronic$2K
- EDAP Technomed Inc$1K
- Axonics, Inc.$1K
- Coloplast$788
- plus $4K from 35 others
Across 4 payments — averaging $850.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$3K
What the payments were for
- Speaking & faculty fees$1,80013%
- Travel & lodging$5994%
- Food & beverage$11,35981%
- Education$1851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XENFORM$1,800
- AquaBeam Robotic System$1,550
- INTERSTIM$648
- SOLYX$506
- Axonics r-SNM System$413
- ALTAVIVA$376
- EnPlace$302
- ALTIS$289
- INTERSTIM ICON$282
- Solyx SIS System$281
- Bulkamid$259
- AquaBeam$246
- BOTOX$136
- UPSYLON$125
- GENERAL - THERAPIES$122
- eCoin Device Kit$102
How this compares
$13,943 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 315 | $244,528 |
| GemtesaVibegron | 74 | $60,132 |
| Tolterodine Tartrate | 327 | $20,124 |
| Trospium Chloride | 387 | $19,790 |
| Solifenacin Succinate | 218 | $13,078 |
| Methenamine Hippurate | 142 | $12,338 |
| Tamsulosin Hcl | 595 | $10,090 |
| Tolterodine Tartrate ErTolterodine Tartrate | 97 | $8,204 |
| Estradiol | 100 | $6,645 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 54 | $3,471 |
| Darifenacin ErDarifenacin Hydrobromide | 16 | $2,624 |
| Oxybutynin Chloride ErOxybutynin Chloride | 79 | $2,225 |
| Trospium Chloride ErTrospium Chloride | 18 | $1,992 |
| Finasteride | 150 | $1,716 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 76 | $1,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $121 | $244,528315 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $186 | $60,13274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.